The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review
Authors
Keywords
-
Journal
CANCER INVESTIGATION
Volume 34, Issue 7, Pages 313-339
Publisher
Informa UK Limited
Online
2016-08-04
DOI
10.1080/07357907.2016.1206117
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I/II lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients
- (2017) S. E. Rivkin et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ovarian cancer treatment: The end of empiricism?
- (2015) Stephanie Lheureux et al. CANCER
- Emerging therapies: angiogenesis inhibitors for ovarian cancer
- (2015) Amanda L Jackson et al. EXPERT OPINION ON EMERGING DRUGS
- Why have ovarian cancer mortality rates declined? Part III. Prospects for the future
- (2015) Victoria Sopik et al. GYNECOLOGIC ONCOLOGY
- Why have ovarian cancer mortality rates declined? Part I. Incidence
- (2015) Victoria Sopik et al. GYNECOLOGIC ONCOLOGY
- A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia
- (2015) H. Hirte et al. GYNECOLOGIC ONCOLOGY
- Nintedanib: From Discovery to the Clinic
- (2015) Gerald J. Roth et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting the microenvironment in ovarian cancer
- (2015) Stephanie Lheureux et al. LANCET ONCOLOGY
- Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
- (2015) Sandro Pignata et al. LANCET ONCOLOGY
- Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer
- (2015) Maria Luisa Gasparri et al. TUMOR BIOLOGY
- A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†
- (2014) I. A. McNeish et al. ANNALS OF ONCOLOGY
- Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904
- (2014) Robert L. Coleman et al. EUROPEAN JOURNAL OF CANCER
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
- (2014) Andreas du Bois et al. JOURNAL OF CLINICAL ONCOLOGY
- Ovarian cancer
- (2014) Gordon C Jayson et al. LANCET
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Interactions of Multitargeted Kinase Inhibitors and Nucleoside Drugs: Achilles Heel of Combination Therapy?
- (2014) V. L. Damaraju et al. MOLECULAR CANCER THERAPEUTICS
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Targeting tyrosine-kinases in ovarian cancer
- (2013) Matteo Morotti et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study
- (2013) R.J. Schilder et al. GYNECOLOGIC ONCOLOGY
- A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma
- (2013) Thomas J. Herzog et al. GYNECOLOGIC ONCOLOGY
- Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma
- (2013) Koji Matsuo et al. GYNECOLOGIC ONCOLOGY
- Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study
- (2013) Ignace B. Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- New perspectives in ovarian cancer treatment
- (2013) Bernd C. Schmid et al. MATURITAS
- A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
- (2012) K. H. Baumann et al. ANNALS OF ONCOLOGY
- New insights into ovarian cancer pathology
- (2012) J. Prat ANNALS OF ONCOLOGY
- The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer
- (2012) Ting Gui et al. Cancer Epidemiology
- Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin
- (2012) C. Jovelet et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Cediranib: a VEGF receptor tyrosine kinase inhibitor
- (2012) Marina Sahade et al. Future Oncology
- Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
- (2012) Russell J. Schilder et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube
- (2012) Ignacio Romero Noguera et al. GYNECOLOGIC ONCOLOGY
- A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma
- (2012) Susana M. Campos et al. GYNECOLOGIC ONCOLOGY
- The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer
- (2011) Q Sheng et al. BRITISH JOURNAL OF CANCER
- Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer
- (2011) Samar Masoumi Moghaddam et al. CANCER AND METASTASIS REVIEWS
- Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study
- (2011) Lubomir Bodnar et al. GYNECOLOGIC ONCOLOGY
- Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group
- (2011) R. Ramasubbaiah et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma
- (2011) S. John Weroha et al. GYNECOLOGIC ONCOLOGY
- A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study
- (2011) Agustin A. Garcia et al. GYNECOLOGIC ONCOLOGY
- Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer
- (2011) Jonathan A. Ledermann et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Current Status of Src Inhibitors in Solid Tumor Malignancies
- (2011) L. N. Puls et al. ONCOLOGIST
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) N. Colombo et al. ANNALS OF ONCOLOGY
- A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
- (2010) J. J. Biagi et al. ANNALS OF ONCOLOGY
- Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer
- (2010) Martin Pölcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer
- (2010) S. K. Chambers et al. CLINICAL CANCER RESEARCH
- Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2
- (2010) C. M. Annunziata et al. CLINICAL CANCER RESEARCH
- Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074)
- (2010) Patricia Pautier et al. GYNECOLOGIC ONCOLOGY
- A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)
- (2010) H. Hirte et al. GYNECOLOGIC ONCOLOGY
- Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment
- (2010) Stephanie V. Blank et al. GYNECOLOGIC ONCOLOGY
- A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
- (2010) Michael Friedlander et al. GYNECOLOGIC ONCOLOGY
- Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer
- (2010) Stephen A. Welch et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
- (2010) Daniela Matei et al. JOURNAL OF CLINICAL ONCOLOGY
- Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
- (2010) Rebecca L Stone et al. LANCET ONCOLOGY
- Angiogenesis and ovarian cancer
- (2009) César Gómez-Raposo et al. Clinical & Translational Oncology
- Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
- (2009) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Diverse molecular pathways in ovarian cancer and their clinical significance
- (2009) Carmela Ricciardelli et al. MATURITAS
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis
- (2008) Daniela Matei et al. CANCER
- Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
- (2008) Halla S. Nimeiri et al. GYNECOLOGIC ONCOLOGY
- Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study
- (2008) Russell J. Schilder et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now